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Global strategies for controlling infections in sub-Saharan
Africa have focused on the ‘big three’: AIDS, tuberculosis
and malaria. Other causes of fever and infection belong to
the category of neglected diseases. It is important in the 21st
century to compile a comprehensive list of infections in sub-
Saharan Africa, in particular for the two types of syndromes
most frequently associated with decreases in life expectancy:
respiratory and diarrhoeal infections.
Regarding diarrhoeal infections, typhoid fever is the sub-
ject of a review on the management of the disease [1]. The
emergence of multidrug resistance and decreased ciproﬂox-
acin susceptibility of Salmonella enterica serovar typhi has
raised the question of what should be the ﬁrst line of anti-
biotic therapy, taking into account that a short course of
treatment, quick effectiveness and prevention of relapse or
chronic faecal carriage are essential. In general, ceftriaxone
is useful as an alternative to ciproﬂoxacin. Chloramphenicol
use is also regaining popularity in developing countries.
However, azithromycin appears to be the best candidate
for the management of typhoid fever both in developing
countries with high prevalence of decreased ciproﬂoxacin
susceptibility and in returned travellers in industrialized
countries. Besides typhoid fever, the prevalence of Trophe-
ryma whipplei in certain areas of Senegal indicates that this
emergent agent probably plays a much neglected role as a
causative agent of diarrhoea and should be explored in the
future [2,3].
Vector-borne diseases play a particularly important part in
Africa. Recent studies have shown that they are the most
frequent causes of fever in both indigenes and travellers. In
particular, Borrelia has been re-discovered [4,5] and the rick-
ettsiae, including Rickettsia felis, which is the object of a
review, have been reported [6]. Rickettsia felis has been
retrieved in arthropods, mainly in the cat ﬂea, Ctenocepha-
lides felis, and has a worldwide distribution. It is interesting
to note that R. felis, which is a rare cause of ﬂea-borne
spotted fever and was ﬁrst described in the USA, is an
unexpectedly common cause of ‘fever of unknown origin’ in
sub-Saharan Africa. Indeed, two studies conducted in Senegal
and Kenya by two different teams at almost the same time
and published in the same issue of Emerging Infectious
Diseases have reported similar data outlining the importance
of R. felis infection in patients with unexplained fever and
without malaria in both countries. Overall, the prevalence of
R. felis DNA in blood specimens was approximately 4%. No
rash was reported. More intriguing is the unanswered
question concerning the complete spectrum of potential
arthropod vectors associated with R. felis. There has been
speculation that patients may have been exposed to ﬂeas.
However, the wide spectrum of arthropod cell lines capable
of supporting R. felis growth suggests a wider spectrum of
potential vectors than has been previously suspected.
Among the neglected parasitic diseases, the ﬁlarioses with
the recent strategy of antibiotic treatment of their Wolbachia
endosymbionts, as well as trypanosomiasis, which has
increased in Africa and has been a source of concern, are
presented in two speciﬁc reviews [7,8]. Wuchereria bancrofti
and Onchocerca volvulus, the species causing lymphatic ﬁlario-
sis and onchocerciasis in Africa, live in mutual symbiosis with
Wolbachia endobacteria, which play a role in inducing the
inﬂammation that leads to symptoms. The Wolbachia endo-
bacteria are also antibiotic targets. Indeed, the standard mi-
croﬁlaricidal drugs ivermectin and albendazole, which are
used in mass drug administration programmes aimed at inter-
rupting transmission, have three major limitations: (i) co-
endemicity of Loa loa, which is a mild nuisance only, with
W. bancrofti or O. volvulus presents an impediment to treat-
ment because of the risk of encephalopathy encountered
with ivermectin and Loa infection; (ii) ivermectin and albenda-
zole do not permanently sterilize female worms; (iii) there is
no clear macroﬁlaricidal effect at the doses currently in use;
as a consequence, repeated rounds of massive drug adminis-
tration in onchocerciasis for many years are required
because of the extended worm lifespan. However, targeting
the Wolbachia endosymbionts, which are present in W. ban-
crofti and O. volvulus (but not in L. loa), with doxycycline has
been shown to lead to sterilization of the female worms and
to have a macroﬁlaricidal effect.
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Human African trypanosomiasis, or sleeping sickness, is
transmitted by the tsetse ﬂy. It is one of the most neglected
tropical diseases, which has led to several problems: (i) the
resurgence of the disease in the late 1990s, which has been
linked to a collapse of surveillance and control activities;
even though a decrease in cases has been recently noted,
many cases certainly remain undiagnosed or unreported
because of a lack of speciﬁc manifestations or because it
occurs in areas that lack surveillance; (ii) the increase of
potential human targets, because of modiﬁcations in tsetse
ﬂy distribution, with the adaptation of some species to areas
with high human population densities, and the emerging tour-
ist destinations increasing the risk for travellers; (iii) the
unlikelihood of the development of a vaccine because of the
high degree of antigenic variability; (iv) the impossibility of
the adoption of control strategies based on preventive che-
motherapy because of the toxicity of existing drugs; and (v)
the complexity of current diagnostic strategies in rural sub-
Saharan Africa. Overall, it is urgent that more practical and
accurate diagnostic tests are developed, as well as new
methods to treat patients and to control transmission by the
tsetse ﬂy.
Among the good news, the absence of a signiﬁcant emer-
gence of the ﬁloviruses causing haemorrhagic fevers (Ebola
and Marburg viruses) and major advances in the understand-
ing of their ecology, virus–host interactions and disease con-
trols, as well as the development of potential antiviral drugs
and candidate vaccines, are greatly encouraging. All of these
advances are discussed in a speciﬁc review [9], including the
recent evidence that bats are natural hosts for ﬁloviruses.
Finally, focus should be turned towards drawing up the rep-
ertoire of manageable infections speciﬁc to Africa so as to
set up effective diagnostic and therapeutic strategies. We
should make sure that focus on the ‘big three’ does not
become a ‘tree’ to hide the ‘forest’ of infections that have
been undocumented and neglected in Africa.
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